No Longer Available EXPANDED_ACCESS NCT04657458

Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment: Expanded Access Protocol for Patients With COVID-19 Associated ARDS

Sponsor: Direct Biologics, LLC

Conditions ARDS Covid19 Cytokine Storm Hypoxia

Interventions ExoFlo

Updated 11 times since 2021 Last updated: Nov 20, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates ARDS and Covid19 and is currently ongoing. Direct Biologics, LLC leads this study, which shows 11 recorded versions since 2026 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

11 versions recorded

Dec 2024 — Present [monthly]

No Longer Available

Status: Available → No Longer Available
Sep 2024 — Dec 2024 [monthly]

Available
Jul 2024 — Sep 2024 [monthly]

Available
Mar 2024 — Jul 2024 [monthly]

Available
May 2023 — Mar 2024 [monthly]

Available

▶ Show 6 earlier versions

Mar 2023 — May 2023 [monthly]

Available
Feb 2023 — Mar 2023 [monthly]

Available
Jun 2022 — Feb 2023 [monthly]

Available
Mar 2022 — Jun 2022 [monthly]

Available
Sep 2021 — Mar 2022 [monthly]

Available
Jan 2021 — Sep 2021 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Direct Biologics, LLC

Data source: Direct Biologics, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.